Adlai Nortye Ltd.
Business
Adlai Nortye Ltd. is a global clinical-stage biotechnology company focused on discovering and developing innovative cancer therapies. It develops a pipeline of small-molecule and antibody drug candidates—including lead programs AN2025 (pan-PI3K inhibitor), AN4005 (oral PD‑L1 inhibitor), AN8025 (tri‑specific antibody) and AN9025 (pan‑RAS(ON) inhibitor)—and advances these through preclinical studies and multi-regional clinical trials. Its operations are organized around research and development, clinical development and regulatory interactions, and partnerships/licensing and CMO-based manufacturing. The company conducts R&D and clinical trials across North America, Europe, Asia, South America and China, with regional headquarters and multinational collaboration channels.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-35.53M |
| Total assets | $34.43M |
| Total liabilities | $42.76M |
| Stockholders' equity | — |
| Operating cash flow | — |